Peer D, and Margalit R (2000). Physicochemical evaluation of a stability-driven approach to drug entrapment in regular and in surface-modified liposomes. Arch. Biochem. Biophys . 383,185–190.
Peer D, Florentin A, and Margalit R (2003). Hyaluronan is a key component in cryoprotection and in formulation of targeted unilamellar liposomes. Biochim. Biophys. Acta .1612, 76-82.
Peer D, and Margalit R (2004). Loading Mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Inter. J. Cancer . 108, 780-789.
Peer D, and Margalit R (2004). Tumor-targeted hyaluronan nano- liposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenografts mouse tumor models. Neoplasia . 6, 343-353.
Peer D, Dekel Y, Melikhov D, and Margalit R (2004). Fluoxetine inhibits MDR extrusion pumps and enhances therapeutic responses to chemotherapy in syngeneic and human xenograft mouse tumor models. Cancer Research . 64, 7562-7569.
Shimaoka M, Kim M, Cohen E, Yang W, Astrof N, Peer D, Salas A, Ferrand A, and Springer TA (2006). AL- 57, a ligand-mimetic antibody to integrin LFA-1, reveals chemokine-induced affinity up-regulation in lymphocytes. Proc. Natl. Acad. Sci. USA .103,13991-13996.
Peer D, and Margalit R (2006). Fluoxetine and reversal of multidrug resistance. Cancer Letters . 237,180-187.
Klausner EA, Peer D, Chapman RL, Multack RF, and Andurkar SV (2007). Corneal gene therapy. Journal of Controlled Release . 124 ,107-133.
* Peer D , Zhu P, Carman CV, Lieberman J, and Shimaoka M (2007). Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function- associated antigen-1. Proc. Natl. Acad. Sci. USA , 104, 4095-4100.
Peer D, Karp JM, Hong S, Farokhzad O, Margalit R, and Langer R (2007). Nanocarriers as an emerging platforms for cancer therapy. Nature Nanotechnology . 2, 751-760.
* Peer D , Park EJ, Morishita Y, Carman CV, and Shimaoka M (2008). Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-Inflammation target. Science . 319, 627-630.
Astrof NS, Peer D, and Shimaoka M (2008). Development & Application of Conformation- Selective Integrin Antibodies. In S. Gad (Editor), Development of Therapeutic Agents . John Wiley & Sons Publishers. In press .
Peer D (2008). Fluoxetine and cancer multidrug resistance extrusion pumps. In M. Schwab (Editor), Cancer Encyclopedia . Springer publishing. 1, 1145-1148.
Imai Y, Park EJ, Peer D, Peixoto A, Cheng G, von Andrian UH, Carman CV, and Shimaoka M (2008). Genetic perturbation of the putative cytoplsmic membrane-proximal salt bridge aberrantly activates alpha4 integrins. Blood . 112(13), 5007-5015. (Cover feature).
Argov M, Kashi R, Peer D, and Margalit R (2009). Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. Cancer Letters . 274 ,118-125.
Peer D, and Shimaoka M (2009). Systemic siRNA delivery to leukocyte-implicated diseases. Cell Cycle . 8, 853-859.
Peer D (2009). Nanocarriers delivering RNAi to cancer cells: from challenge to cautious optimism. Therapy . 6(3), 293-296.
Ben-Arie N*, Kedmi R *, and Peer D (2009). Integrin-targeted nanoparticles. In Shimaoka M (Editor) Integrins . Methods in Molecular Biology . Humana Press. In press . * denoted equal contribution.
Kedmi R, and Peer D (2009). RNAi nanoparticles in the service of personalized medicine. Nanomedicine . 4(8), 853-855.
Kim S-S*, Peer D*, Kumar P*, Subramanya S, Wu H, Asthana D, Habiro K, Yang Y-G, N.
Manjunath, Shimaoka M and Shankar P (2010). RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Molecular Therapy . 18, 370-376. * denotes equal contribution.
Weinstein S, and Peer D (2010). Systemic siRNA Delivery: A Progress Report. Nanotechnology Law & Business . 6(4), 454-466.
Dearling JLJ, Voss S, Dunning P, Park EJ, Fahey F, Treves T Solapino S., Shimaoka M, Packard AB, and Peer D (2010). Detection of Intestinal Inflammation by microPET Imaging Using a 64Cu-Labeled Anti-b7 Integrin Antibody.Inflammatory bowel diseases. 16(9):1458-66.
Weinstein S., and Peer D (2010). RNAi Nanomedicines: challenges and opportunities
within the immune system. Nanotechnology. 21(23), 232001, 1-13.
Kedmi R*, Ben-Arie N*, and Peer D (2010). The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials 31, 6867-6875.
Rivkin I, Cohen K, Koffler J, Melichov D., Peer D*, and Margalit R* (2010). Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors. Biomaterials 31, 7106-7114.
Peer D (2010). Induction of therapeutic gene silencing in leukocyte-implicated diseases by targeted and stabilized nanoparticles: A mini-review. Journal of Controlled Release 148, 63-68.
Cohen-Kupiec R, Weinstein S, Kantor G, Peer D, Weil M. (2010). IKAP/hELP1 downregulation in neuroblastoma cells causes enhanced cell adhesion mediated by contactin overexpression. Cell adhesion & migration Oct 8;4(4).
Elfakess R. and Peer D. (2010). Overcoming RNAi transduction in leukocytes using targeted and stabillized nanoparticles. IDrugs Sep 13(9):626-31.
Drug E, Landesman-Milo D, Belgorodsky B, Ermakov N, Frenkel-Pinter M, Fadeev L, Peer D, Gozin M (2011). Enhanced Bioavailability of Polyaromatic Hydrocarbons in the Form of Mucin Complexes. Chemical research in toxicology. 24(3):314-20.
Kim SS, Subramanya S, Peer D, Shimaoka M, Shankar P. (2011). Antibody-Mediated Delivery of siRNAs for Anti-HIV Therapy. Methods in molecular biology 721:339-353.
Bachar G, Cohen K, Hod R, Feinmesser R, Mizrachi A, Shpitzer T, Katz O, Peer D. (2011). Hyaluronan-grafted particle clusters loaded with Mitomycin C as selective nanovectors for primary head and neck cancers. Biomaterials Jul;32(21):4840-8
Peer D, Lieberman J. (2011). Special delivery: targeted therapy with small RNAs. Gene therapy Dec;18(12):1127-33.
Mizrahy S, Raz SR, Hasgaard M, Liu H, Soffer-Tsur N, Cohen K, Dvash R, Landsman-Milo D, Bremer MG, Moghimi SM, Peer D. (2011). Hyaluronan-coated nanoparticles: The influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. Journal of Controlled Release. 2011 Dec 10;156(2):231-8.
Breiner-Goldstein E, Evron Z, Frenkel M, Cohen K, Nir Meiron K, Peer D, Roichman Y,Flescher E, and Fridman M (2011). Targeting Anthracycline-resistant Tumor Cells with Synthetic Aloe-emodin Glycosides. ACS Medicinal chemistry letters, 2, 528-531.
Ben-Arie N, Kedmi R. and Peer D (2012). Integrin-Targeted Nanoparticles for siRNA Delivery. Methods Mol Biol .757, 497-507.
Moghimi SM, Peer D, Langer R (2011). Reshaping the Future of Nanopharmaceuticals: Ad ludicium. ACS Nano. Nov 22;5(11):8454-8.
Mizrahy S, Peer D (2012). Polysaccharides as building blocks for nanotherapeutics. Chem Soc Rev. 41, 2623–2640
Solmesky LJ, Shuman M, Goldsmith M, Weil M, Peer D (2011). Assessing cellular toxicities in fibroblasts upon exposure to lipid-based nanoparticles: a high content analysis approach. Nanotechnology. 2011 Nov 21;22(49):494016.
Goldsmith M, Mizrahy S, Peer D (2011). Grand challenges in modulating the immune response with RNAi nanomedicines. Nanomedicine (Lond) . 2011 Dec;6(10):1771-85.
Srinivasan C, Peer D, and Shimaoka M (2012). Integrin Targeted Stabilized Nanoparticles for an Efficient Delivery of siRNAs in vitro and in vivo. Methods in Molecular Biology . 2012;820:105-16.
Landsman –Milo D., and Peer D (2012). Modulating the immune response with liposomes. Journal of Controlled Release . 161, 600-608.
Moyano D., Goldsmith M., Solfiell D., Landesman-Milo D., Miranda O., Peer D.* and Rotello VM* (2012). Hydrophobicity Dictates Immune Response. Journal of American Chemical Society 2012 Mar 7;134(9):3965-7.
Barenholz Y and Peer D (2012). Liposomes, lipid biophysics, and sphingolipid research: from basic to translation research. Chemistry & Physics of Lipids 165, 363-364.
Barenholz Y., and Peer D (2012). Liposomes and other assemblies as drugs and nano-drugs: From basic and translational research to the clinics. Journal of Controlled Release 160(2), 115-116.
Peer D (2012). Immunotoxicity-derived from manipulating leukocytes with Lipid-based nanoparticles. Advance Drug Delivery Reviews. 64 (15), 1738-1748
Weinstein S., Emmanuel R., Jacobi A.M., Abraham A., Behlke M.A., Sprague A.G., Novobrantseva T.I., Nagler A., and Peer D (2012). RNA inhibition highlights Cyclin D1 as a potential Therapeutic Target for Mantle Cell Lymphoma . PLoS ONE. e43343,7(8), 1-5.
Daka A., and Peer D (2012). RNAi-based Nanomedicines for Targeted Personalized Therapy. Advanced Drug Delivery Reviews. 64, 1508-1521 .
Landesman-Milo D., Goldsmith M., Levitn –Ben Arie S., Witenberg B., Brown E., Leibovitch S., Azriel S., Tabak S., Morad V., and Peer D (2012). Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells. Cancer Letters , 334 , 221-227.
Vourp-Jensen T and Peer D (2012). Nanotoxicity and the Importance of being earnest.
Advance Drug Delivery Reviews. 64(15), 1661–1662.
Peer D (2013). A daunting task: manipulating leukocytes’ function with RNAi. Immunological Reviews. 253; 185-197.
Elinav E. and Peer D (2013). Harnessing Nanomedicine For Mucosal Theranostics – A Silver Bullet At Last? ACS Nano. 7(4): 2883-90.
Emmanuel R., Weinstein S., Landesman-Milo D. and Peer D (2013). eiF3c: A potential
therapeutic target for cancer. Cancer Letters, 336, 158–166.
Landesman-Milo D., and Peer D (2013). Toxicity profiling of several common RNAi-based nanomedicines: A comparative study. Drug Delivery and Translational Research. In press.
Howard KA and Peer D (2013): Providing the full picture: a mandate for standardizing nanoparticle-based drug delivery. Nanomedicine (Lond.). 8 (7), 1-3.
Dvash R., Khatchatouriants A, Solmesky LJ, Wibroe PP., Weil M., Moghimi SM., and Peer D (2013). Structural profiling and biological performance of phospholipid-hyaluronan functionalized single-walled carbon nanotubes. Journal of Controlled Released , 170, 295-305.
Dahan L., Huang L., Kedmi R., Behlke MA, and Peer D (2013). SNP detection in mRNA in living cells using allele specific FRET probes. PLoS ONE. In press
Mizrahy S., Landesman-Milo D., and Peer D (2013). Sweet fairytale: Carbohydrates as Backbones for Glyconanomedicine. Israel Journal of Chemistry. In press.
Rosenblum D. and Peer D (2013). Omics-based nanomedicine: The future of personalized oncology. Cancer Letters. In press
Wang X., Peer D., and Petersen B (2013). Molecular and Cellular Therapies: New Challenges and Opportunities. Molecular and Cellular Therapies. In press
* See also commentaries:
• siRNA delivery to activated leukocytes (2007). Proc. Natl. Acad. Sci. USA. 104, 3669
• The art of assembly (2008). Science. 319, 578-579.
• siRNA nanoparticles, fully loaded (2008). Nature Chemical Biology. 4, 167.
• Escorting siRNA (2008). Nature Reviews Molecular Cell Biology. 9, 189.
• siRNA with Guts (2008). Nature Biotechnology. 26, 403-405.
• Biomedicine: The new gold standard (2013). Nature. 495, s14-s16.
- Dan Peer, Handbook of Harnessing Biomaterials in Nanomedicine: Preparation, Toxicity, and Applications. Pan Stanford Publishing, CRC Press 2012.
- Dan Peer, Nanotechnology for delivery of therapeutic nucleic acids. Pan Stanford Publishing, CRC Press, 2013.